Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

Boylan rates Amgen stock a hold. Beyond MariTide, investors are also closely watching olpasiran. Amgen is developing it for patients with elevated lipoprotein A, or Lp(a). Like cholesterol ...

An ribonucleic acid (RNA) inhibitor, olpasiran (Amgen), which has shown it can lower lipoprotein(a) [Lp(a)] levels in patients with cardiovascular disease (CVD), has demonstrated in a phase 2 ...

A new study published in the Journal of American Medical Association showed that the innovative small interfering RNA (siRNA) medication olpasiran (Amgen) can effectively reduce lipoprotein(a) ...

Olpasiran (manufactured by Amgen), a small interfering RNA, blocks Lp(a) production by inducing degradation of apolipoprotein(a) messenger RNA (mRNA). Apolipoprotein(a) is a major protein component of ...